What Is Selank? A Researcher’s Guide to the Calming Russian Peptide

// Cognitive · Compound Profile · Research Education · Titanborn Research

Selank is the calm to Semax’s focus. They came out of the same Moscow laboratory, share the same clever stabilization trick, and are studied together so often the research community calls them “sister peptides.” But where Semax was engineered from a hormone fragment to sharpen cognition, Selank was engineered from an immune peptide — and its standout reported property is something no Western anxiety drug achieves cleanly: anxiety reduction comparable to benzodiazepines, reportedly without the sedation, cognitive fog, or dependence.

Like Semax, Selank carries a real Russian clinical history and the same catch — most of the human evidence is Russian and hasn’t been replicated in large Western trials. This guide covers what it is, its surprising immune-system origin, how it works, what the research shows, and how it pairs with Semax.

What Selank Actually Is

A synthetic heptapeptide — seven amino acids, sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP).

Built from an immune peptide, not a brain hormone. This is the surprising part: Selank is a synthetic analog of tuftsin, a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) cleaved from the heavy chain of immunoglobulin G (IgG) — an antibody. Tuftsin’s natural job is immune: it stimulates phagocytosis and activates macrophages and neutrophils.

The same Pro-Gly-Pro trick as Semax. Russian researchers added a Pro-Gly-Pro tail to tuftsin’s C-terminus. This did two things: increased metabolic stability (protecting it from rapid enzymatic breakdown), and — remarkably — shifted the activity from primarily immune-stimulating toward neuromodulatory. The result kept some immune properties but gained the anxiolytic and nootropic effects Selank is known for.

Also designated TP-7; “Selank” is its approved drug name in Russia.

Made synthetically for research and (in Russia) clinical use, typically as an intranasal solution.

Notice the shared engineering signature with Semax: both take a natural short peptide and bolt on a Pro-Gly-Pro tail for stability. That’s the fingerprint of the same research program.

Where It Came From: The Same Lab as Semax

Selank’s origin runs directly parallel to Semax’s — by design:

It was developed (in the 1990s) at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow — the same institute that produced Semax — in cooperation with the V.V. Zakusov Research Institute of Pharmacology.

The starting material, tuftsin, is a well-characterized immune tetrapeptide. Russian researchers took that molecule and engineered the more stable, brain-active Selank from it, in the same Russian neuropeptide research tradition associated with Semax. Like Semax, Selank was eventually approved in Russia — in its case for generalized anxiety disorder and neurasthenia.

So the two peptides aren’t just thematically similar — they’re institutional siblings from one Russian neuropeptide program, which is exactly why they’re studied and discussed as a pair.

How It Works

Selank’s mechanism is multi-target, and the headline is its GABA effect:

GABA system modulation (the anxiolytic engine). Clinical studies reported Selank’s anxiolytic effect comparable to classical benzodiazepines, which work by enhancing GABA’s inhibitory signaling. Gene-expression studies show Selank affects genes involved in GABAergic neurotransmission, suggesting it acts in part through the GABAergic system.

The crucial difference from benzodiazepines: Selank’s defining reported feature is anxiolysis without sedation, cognitive impairment, or dependence — a combination Western benzodiazepines don’t achieve cleanly (they typically sedate and carry dependence risk).

Enkephalin stabilization. Selank inhibits the breakdown of enkephalins (the body’s own opioid-like signaling molecules), prolonging their activity — proposed as part of its calming and mood effects.

BDNF upregulation. Like Semax, Selank influences brain-derived neurotrophic factor — the overlap that gives both peptides a nootropic/neuroprotective dimension.

Immune modulation (its tuftsin heritage). It retains immune effects — research shows it may modulate cytokines such as IL-6 and influence T-helper-cell balance in animal models, appearing to normalize immune function rather than broadly suppress or stimulate it.

Benzodiazepine interaction. Notably, one rat study found Selank can enhance the effect of diazepam — a mechanistically interesting finding.

The contrast with Semax writes itself: Semax pushes cognition up (BDNF + dopaminergic/stimulating); Selank brings anxiety down (GABA + calming) — without sedating. Both touch BDNF, which is the shared thread. Accelerator and brake, from the same garage.

What the Research Shows — and the Honest Catch

Selank’s evidence profile closely mirrors Semax’s, with the same strengths and the same limitation:

The real clinical footprint (in Russia): Selank is approved in Russia for generalized anxiety disorder and used as a nootropic — a genuine clinical adoption, not just a lab curiosity. Clinical studies reported anxiolytic effects comparable to benzodiazepines, and decades of preclinical and early clinical research cover anxiety, stress response, memory/learning, and immune modulation.

The honest catch (same as Semax):

The clinical evidence is overwhelmingly Russian. As with Semax, the human trial data is concentrated in Russian-language research and has not been replicated in large Western randomized controlled trials.

Much of the mechanistic data is preclinical — animal models and cell cultures. The anxiolytic-vs-benzodiazepine comparisons, the immune effects, and the BDNF findings draw heavily on rats and lab models, and do not by themselves constitute verified therapeutic actions in humans.

No FDA or EMA approval — like Semax, it’s regulatorily invisible in the West. And the clean “no sedation, no dependence” profile, while a genuine selling point in the Russian literature, has limited rigorous independent Western confirmation.

The fair framing, identical in shape to Semax: a real registered medicine somewhere, with an unusually clean reported profile and solid mechanistic science — but the independent Western confirmation that would settle it hasn’t been done.

The Regulatory Picture (As of Mid-2026)

Not FDA- or EMA-approved.

An approved medicine in Russia for generalized anxiety disorder and as a nootropic.

An earlier chapter of the FDA peptide story than its siblings. Here’s a distinction worth getting right, because it sets Selank apart from BPC-157, TB-500, and Semax. Selank acetate (TP-7) was one of five peptides — alongside AOD-9604, CJC-1295, ipamorelin, and thymosin alpha-1 — removed from Category 2 back on September 27, 2024 (its nomination withdrawn), well ahead of the bigger April 2026 reversal. It was then referred to the FDA’s Pharmacy Compounding Advisory Committee and reviewed in late 2024 — but unlike the peptides on the July 2026 docket, Selank’s path to the 503A bulks list did not clear at that review. So Selank sits in a more uncertain, already-reviewed limbo rather than riding the fresh 2026 momentum.

For a research-use-only context: Selank is supplied for laboratory research, not human use — and its approval status in Russia does not change its U.S. legal standing.

Where the Research May Be Heading

The replication gap is the headline frontier — exactly as with Semax. Independent Western trials confirming the benzodiazepine-comparable anxiolytic effect (and the clean safety profile) would be transformative for how seriously Selank is taken globally.

Neurodegenerative disease. A 2020 review (Shadrina et al.) explicitly framed Selank’s prospects for anxiety disorders and neurodegenerative diseases — an expanding scope.

The benzodiazepine-interaction finding (enhancing diazepam’s effect) is mechanistically intriguing and a live research thread.

The immune-neuro crossover. Because it descends from an immune peptide but acts on the brain, Selank sits at an interesting intersection that researchers continue to probe.

Why Purity and Identity Testing Matter for Selank Specifically

It’s a precise seven-amino-acid sequence (TKPRPGP). As with any defined peptide, a synthesis error or truncation yields a different molecule. Only mass-spec identity testing confirms the exact sequence is present.

Tuftsin-related impurities are a relevant consideration — since Selank is built on the tuftsin fragment, confirming you have the full stabilized heptapeptide (not tuftsin or a partial sequence) matters for research validity.

Unregulated supply puts verification on the buyer. Like every research peptide outside formal oversight, a third-party Certificate of Analysis confirming identity and purity is the dividing line between defined research material and an assumption.